Tag Archives: FENopta

Roche’s Fenebrutinib Demonstrates Promising Results with Low Relapse Rates and No Disability Progression in Phase II Multiple Sclerosis Study

(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release